Project Summary Our project aims to develop a novel technology platform for delivering macromolecules intracellularly overcoming the challenge of endosomal barriers. Justification for the AKTA Pure 25 M chromatography system stems from the growing demand for isolating and purifying biological nanoparticles, like gectosomes, crucial for therapeutic development. Existing methods lack scalability and reproducibility. The AKTA Pure 25 M's automation, scalability, and compatibility with high-resolution SEC columns are essential for our research. It will enhance purification efficiency, improving gectosome quality and scalability, accelerating our research timeline. In summary, the acquisition of the AKTA Pure 25 M will provide a significant boost to our experimental studies, enhance research efficiency, and foster collaboration within our research community. This investment will catalyze advancements in intracellular biologic delivery, benefiting both basic research and therapeutic development endeavors.